CA3146023A1 - Antibodies binding igc2 of igsf11 (vsig3) and uses thereof - Google Patents

Antibodies binding igc2 of igsf11 (vsig3) and uses thereof Download PDF

Info

Publication number
CA3146023A1
CA3146023A1 CA3146023A CA3146023A CA3146023A1 CA 3146023 A1 CA3146023 A1 CA 3146023A1 CA 3146023 A CA3146023 A CA 3146023A CA 3146023 A CA3146023 A CA 3146023A CA 3146023 A1 CA3146023 A1 CA 3146023A1
Authority
CA
Canada
Prior art keywords
igsf11
abp
domain
protein
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3146023A
Other languages
English (en)
French (fr)
Inventor
Jonas ZANTOW
Stefanie Urlinger
Joerg Thomas Regula
Sabrina GENSSLER
Maximilian Aigner
Simone BRAENDLE
Stefan BISSINGER
Tillman MICHELS
Nisit KHANDELWAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IOmx Therapeutics AG
Original Assignee
IOmx Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IOmx Therapeutics AG filed Critical IOmx Therapeutics AG
Publication of CA3146023A1 publication Critical patent/CA3146023A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
CA3146023A 2019-07-05 2020-07-06 Antibodies binding igc2 of igsf11 (vsig3) and uses thereof Pending CA3146023A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19184708.6 2019-07-05
EP19184708 2019-07-05
PCT/EP2020/069014 WO2021005009A1 (en) 2019-07-05 2020-07-06 Antibodies binding igc2 of igsf11 (vsig3) and uses thereof

Publications (1)

Publication Number Publication Date
CA3146023A1 true CA3146023A1 (en) 2021-01-14

Family

ID=67211532

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3146023A Pending CA3146023A1 (en) 2019-07-05 2020-07-06 Antibodies binding igc2 of igsf11 (vsig3) and uses thereof

Country Status (9)

Country Link
US (1) US20220372138A1 (enExample)
EP (1) EP3994171A1 (enExample)
JP (1) JP2022538688A (enExample)
KR (1) KR20220051164A (enExample)
CN (1) CN114401992A (enExample)
AU (1) AU2020311579A1 (enExample)
CA (1) CA3146023A1 (enExample)
IL (1) IL289640A (enExample)
WO (2) WO2021005009A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220051164A (ko) * 2019-07-05 2022-04-26 아이오엠엑스 테라퓨틱스 아게 Igsf11 (vsig3)의 항체 결합 igc2 및 이의 용도
KR20230163144A (ko) * 2022-05-23 2023-11-30 웰마커바이오 주식회사 Igsf1의 c-말단에 결합하는 항체 및 이의 용도
CN115184611B (zh) * 2022-08-01 2023-02-03 中国医学科学院北京协和医院 子宫内膜癌分层相关的标志物及其应用

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5817311A (en) 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
WO1997003436A1 (en) 1994-06-09 1997-01-30 Clifford Ellsworth Boehm system clarinet having improved a key mechanism
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5567895A (en) 1995-03-09 1996-10-22 Aspri; Roberto Sound reverberator mounted in a sound box of a string musical instrument
US5802497A (en) 1995-07-10 1998-09-01 Digital Equipment Corporation Method and apparatus for conducting computerized commerce
WO1997003404A1 (en) 1995-07-11 1997-01-30 Hitachi, Ltd. Service offering system
BE1009744A4 (fr) 1995-07-13 1997-07-01 Fleury Annette Appareil de distribution automatique de matiere en feuille de conditionnement.
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US5891212A (en) 1997-07-14 1999-04-06 Aeroquip Corporation Apparatus and method for making uniformly
DE69805415T2 (de) 1997-07-14 2002-10-17 Russinsky Ltd., Cork Verfahren zur isomerisierung von tilidin
AU8333398A (en) 1997-07-14 1999-02-10 Novo Nordisk A/S Injection member
US6216765B1 (en) 1997-07-14 2001-04-17 Arizona State University Apparatus and method for manufacturing a three-dimensional object
DK0996613T3 (da) 1997-07-15 2003-03-03 Russinsky Ltd Fremstilling af rent cis-tramadol-hydrochlorid
RU2115514C1 (ru) 1997-07-15 1998-07-20 Московский энергетический институт (Технический университет) Способ получения монодисперсных сферических гранул
WO1999003611A1 (en) 1997-07-15 1999-01-28 Co.Fi.Te S.A. Method and plant for the production of frustoconical pipes
BR9810600A (pt) 1997-07-16 2000-07-11 Ciba Sc Holding Ag Compostos espiro-poliglicidila e seu uso em resinas epóxi
FR2766178B1 (fr) 1997-07-16 2000-03-17 Oreal Nouvelles bases d'oxydation cationiques, leur utilisation pour la teinture d'oxydation des fibres keratiniques, compositions tinctoriales et procedes de teinture
US6384230B1 (en) 1997-07-16 2002-05-07 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
FR2766113B1 (fr) 1997-07-16 1999-09-17 Usinor Procede de demarrage d'une operation de coulee continue des metaux
DE19730637A1 (de) 1997-07-17 1999-01-21 Ald Vacuum Techn Gmbh Verfahren zum gerichteten Erstarren einer Metallschmelze und Gießvorrichtung zu seiner Durchführung
WO1999003628A1 (de) 1997-07-17 1999-01-28 Wto Werkzeug-Einrichtungen Gmbh Vorrichtung zur aufnahme eines werkzeugs oder trägerteils bei einer werkzeugmaschine oder spindel
CA2297072A1 (en) 1997-07-17 1999-01-28 Baxter Healthcare S.A. Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
FR2766083A1 (fr) 1997-07-17 1999-01-22 Future Medical Systems Procede de determination de perte de liquide lors d'une operation
RU2193032C2 (ru) 1997-07-17 2002-11-20 Рон-Пуленк Роре С.А. Производные полигидроксиалкилпиразинов, их получение и содержащие их лекарственные средства
JP2001515839A (ja) 1997-07-18 2001-09-25 ジョージタウン・ユニバーシティ 二環式向代謝性グルタミン酸受容体リガンド
CA2295831A1 (en) 1997-07-18 1999-01-28 Vasca, Inc. Method and apparatus for percutaneously accessing an implanted port
GB9715030D0 (en) 1997-07-18 1997-09-24 British Biotech Pharm Metalloproteinase inhibitors
DE19731021A1 (de) 1997-07-18 1999-01-21 Meyer Joerg In vivo abbaubares metallisches Implantat
FR2766185B1 (fr) 1997-07-18 2001-06-15 Rhone Poulenc Rorer Sa Medicaments contenant en tant que principe actif au moins un derive substitue de polyhydroxylalkylpyrazines, les nouveaux derives polyhydroxylalkylpyrazines et leur preparation
SE9702744D0 (sv) 1997-07-18 1997-07-18 Hoeganaes Ab Soft magnetic composites
US6177272B1 (en) 1997-07-21 2001-01-23 The Regents Of The University Of Michigan Method for treating vascular proliferative diseases with p27 and fusions thereof
CN1270531A (zh) 1997-07-21 2000-10-18 普罗格特-甘布尔公司 用洗涤剂组合物卫生洗涤携污物的方法
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
NZ513144A (en) 1999-02-05 2003-05-30 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
WO2001055301A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2340499T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
US20040248251A1 (en) 2001-07-17 2004-12-09 Lal Preeti G Receptors and membrane associated proteins
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
JP2003245084A (ja) 2001-12-20 2003-09-02 Morinaga Milk Ind Co Ltd 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
EP1513934B1 (en) 2002-06-06 2011-03-02 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
AU2003258714A1 (en) 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
FR2861080B1 (fr) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
FR2871633A1 (fr) 2004-06-10 2005-12-16 France Telecom Procede de reduction du bruit de phase lors de la reception d'un signal ofdm, recepteur, programme et support
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
ATE453716T1 (de) 2004-08-03 2010-01-15 Geneart Ag Verfahren zur modulation der genexpression durch änderung des cpg gehalts
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
WO2007016306A2 (en) 2005-08-01 2007-02-08 Psivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
MX362981B (es) 2012-03-27 2019-02-28 Curevac Ag Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
BR112014029417B1 (pt) 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
US20170184604A1 (en) 2014-05-22 2017-06-29 The General Hospital Corporation Dd1alpha receptor and uses thereof in immune disorders
CA2969730A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
WO2018027042A1 (en) * 2016-08-03 2018-02-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
CN107034235A (zh) * 2017-05-19 2017-08-11 尹荣 联合靶向pd‑1及egfr的嵌合性抗原t细胞肿瘤免疫方法
EP3508499A1 (en) * 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
EP3755350A4 (en) 2018-02-23 2021-11-03 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF VISTA AND HIS ASSOCIATION PARTNER
WO2020006118A1 (en) 2018-06-26 2020-01-02 Ribonova Inc. Systems and methods for computing measurements for mitochondrial diseases
KR20220051164A (ko) * 2019-07-05 2022-04-26 아이오엠엑스 테라퓨틱스 아게 Igsf11 (vsig3)의 항체 결합 igc2 및 이의 용도

Also Published As

Publication number Publication date
KR20220051164A (ko) 2022-04-26
CN114401992A (zh) 2022-04-26
AU2020311579A1 (en) 2022-02-03
US20220372138A1 (en) 2022-11-24
WO2021005009A1 (en) 2021-01-14
IL289640A (en) 2022-03-01
EP3994171A1 (en) 2022-05-11
WO2022008514A1 (en) 2022-01-13
JP2022538688A (ja) 2022-09-05

Similar Documents

Publication Publication Date Title
CN115066436B (zh) 靶向cd276抗原的抗体和cd276抗原的其他调节剂及其用途
EP3148580B1 (en) Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
US9751942B2 (en) Anti-LAMP5 antibody and utilization thereof
WO2018115859A1 (en) Multispecific antibody with combination therapy for immuno-oncology
TW201803905A (zh) 用於免疫腫瘤學之多重專一性抗體
EP3559041A1 (en) Multispecific antibody with combination therapy for immuno-oncology
WO2022008514A1 (en) Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
EP3015115A1 (en) Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
US20210061908A1 (en) Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
EP4491230A1 (en) Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
WO2024133940A2 (en) Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
US20230406961A1 (en) Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
US20240010720A1 (en) Antibodies binding igv of igsf11 (vsig3) and uses thereof
WO2026003224A2 (en) Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
HK1235681B (en) Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20240812

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260129

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260204